Skip to main content
PMC home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 2000 Mar 21;162(6):827–833.

Chronic viral hepatitis C: management update

K S Gutfreund 1, V G Bain 1
PMCID: PMC1231279  PMID: 10750473

Abstract

The management of chronic viral hepatitis C is evolving rapidly. Monotherapy with interferon, the accepted standard of treatment until recently, achieves only a modest sustained virological response rate of 15%. Combination treatment with alpha-2b interferon and ribavirin has been shown to increase sustained response rates to 40% in patients who have never been treated with interferon and to 50% in those who have relapsed following monotherapy with interferon. However, side effects, which have led to the discontinuation of combination treatment in a significant proportion of patients, must be carefully monitored. Treatment with interferon alpha-2b and ribavirin has now been approved in Canada, but the selection and monitoring of patients suitable for combination treatment requires special expertise. Although improvements in current therapeutic options may be possible with more frequent, higher doses or long-acting forms of interferon together with ribavirin, low sustained response rates (i.e., below 30%) for patients with hepatitis C virus genotype 1 emphasize the need for novel antiviral medications that will target the functional sites of the HCV genome.

Full Text

The Full Text of this article is available as a PDF (313.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alberti A., Chemello L., Noventa F., Cavalletto L., De Salvo G. Therapy of hepatitis C: re-treatment with alpha interferon. Hepatology. 1997 Sep;26(3 Suppl 1):137S–142S. doi: 10.1002/hep.510260724. [DOI] [PubMed] [Google Scholar]
  2. Alberti A., Pontisso P., Chemello L., Fattovich G., Benvegnù L., Belussi F., De Mitri M. S. The interaction between hepatitis B virus and hepatitis C virus in acute and chronic liver disease. J Hepatol. 1995;22(1 Suppl):38–41. [PubMed] [Google Scholar]
  3. Alter M. J. Epidemiology of hepatitis C. Hepatology. 1997 Sep;26(3 Suppl 1):62S–65S. doi: 10.1002/hep.510260711. [DOI] [PubMed] [Google Scholar]
  4. Barbaro G., Di Lorenzo G., Soldini M., Giancaspro G., Bellomo G., Belloni G., Grisorio B., Annese M., Bacca D., Francavilla R. Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: an Italian multicenter, randomized, controlled, clinical study. Am J Gastroenterol. 1998 Dec;93(12):2445–2451. doi: 10.1111/j.1572-0241.1998.00702.x. [DOI] [PubMed] [Google Scholar]
  5. Barrera J. M., Bruguera M., Ercilla M. G., Gil C., Celis R., Gil M. P., del Valle Onorato M., Rodés J., Ordinas A. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology. 1995 Mar;21(3):639–644. [PubMed] [Google Scholar]
  6. Benvegnù L., Chemello L., Noventa F., Fattovich G., Pontisso P., Alberti A. Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer. 1998 Sep 1;83(5):901–909. doi: 10.1002/(sici)1097-0142(19980901)83:5<901::aid-cncr15>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  7. Bizollon T., Ducerf C., Trepo C., Mutimer D. Hepatitis C virus recurrence after liver transplantation. Gut. 1999 Apr;44(4):575–578. doi: 10.1136/gut.44.4.575. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Chiaramonte M., Stroffolini T., Vian A., Stazi M. A., Floreani A., Lorenzoni U., Lobello S., Farinati F., Naccarato R. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer. 1999 May 15;85(10):2132–2137. [PubMed] [Google Scholar]
  9. Colombo M. The natural history of hepatitis C. Baillieres Clin Gastroenterol. 1996 Jul;10(2):275–288. doi: 10.1016/s0950-3528(96)90007-x. [DOI] [PubMed] [Google Scholar]
  10. Davis G. L., Esteban-Mur R., Rustgi V., Hoefs J., Gordon S. C., Trepo C., Shiffman M. L., Zeuzem S., Craxi A., Ling M. H. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med. 1998 Nov 19;339(21):1493–1499. doi: 10.1056/NEJM199811193392102. [DOI] [PubMed] [Google Scholar]
  11. Davis G. L., Lau J. Y. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology. 1997 Sep;26(3 Suppl 1):122S–127S. doi: 10.1002/hep.510260721. [DOI] [PubMed] [Google Scholar]
  12. Farci P., Alter H. J., Wong D., Miller R. H., Shih J. W., Jett B., Purcell R. H. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med. 1991 Jul 11;325(2):98–104. doi: 10.1056/NEJM199107113250205. [DOI] [PubMed] [Google Scholar]
  13. Féray C., Caccamo L., Alexander G. J., Ducot B., Gugenheim J., Casanovas T., Loinaz C., Gigou M., Burra P., Barkholt L. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology. 1999 Sep;117(3):619–625. doi: 10.1016/s0016-5085(99)70454-3. [DOI] [PubMed] [Google Scholar]
  14. Gavier B., Martínez-González M. A., Riezu-Boj J. I., Lasarte J. J., Garcia N., Civeira M. P., Prieto J. Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C. Gastroenterology. 1997 Nov;113(5):1647–1653. doi: 10.1053/gast.1997.v113.pm9352868. [DOI] [PubMed] [Google Scholar]
  15. Heathcote E. J., Keeffe E. B., Lee S. S., Feinman S. V., Tong M. J., Reddy K. R., Albert D. G., Jr, Witt K., Blatt L. M. Re-treatment of chronic hepatitis C with consensus interferon . Hepatology. 1998 Apr;27(4):1136–1143. doi: 10.1002/hep.510270431. [DOI] [PubMed] [Google Scholar]
  16. Hino K., Sainokami S., Shimoda K., Niwa H., Iino S. Clinical course of acute hepatitis C and changes in HCV markers. Dig Dis Sci. 1994 Jan;39(1):19–27. doi: 10.1007/BF02090055. [DOI] [PubMed] [Google Scholar]
  17. Hoofnagle J. H. Therapy of viral hepatitis. Digestion. 1998 Aug;59(5):563–578. doi: 10.1159/000007532. [DOI] [PubMed] [Google Scholar]
  18. Keeffe E. B., Hollinger F. B. Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group. Hepatology. 1997 Sep;26(3 Suppl 1):101S–107S. doi: 10.1002/hep.510260718. [DOI] [PubMed] [Google Scholar]
  19. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med. 1999 Apr 22;340(16):1228–1233. doi: 10.1056/NEJM199904223401602. [DOI] [PubMed] [Google Scholar]
  20. Kowdley K. V. Does interferon therapy prevent hepatocellular carcinoma in patients with chronic hepatitis C? Gastroenterology. 1999 Sep;117(3):738–739. doi: 10.1016/s0016-5085(99)70471-3. [DOI] [PubMed] [Google Scholar]
  21. Lok A. S., Chien D., Choo Q. L., Chan T. M., Chiu E. K., Cheng I. K., Houghton M., Kuo G. Antibody response to core, envelope and nonstructural hepatitis C virus antigens: comparison of immunocompetent and immunosuppressed patients. Hepatology. 1993 Sep;18(3):497–502. [PubMed] [Google Scholar]
  22. Louie M., Low D. E., Feinman S. V., McLaughlin B., Simor A. E. Prevalence of bloodborne infective agents among people admitted to a Canadian hospital. CMAJ. 1992 Apr 15;146(8):1331–1334. [PMC free article] [PubMed] [Google Scholar]
  23. Major M. E., Feinstone S. M. The molecular virology of hepatitis C. Hepatology. 1997 Jun;25(6):1527–1538. doi: 10.1002/hep.510250637. [DOI] [PubMed] [Google Scholar]
  24. Marcellin P., Boyer N., Gervais A., Martinot M., Pouteau M., Castelnau C., Kilani A., Areias J., Auperin A., Benhamou J. P. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med. 1997 Nov 15;127(10):875–881. doi: 10.7326/0003-4819-127-10-199711150-00003. [DOI] [PubMed] [Google Scholar]
  25. Marcellin P., Lévy S., Erlinger S. Therapy of hepatitis C: patients with normal aminotransferase levels. Hepatology. 1997 Sep;26(3 Suppl 1):133S–136S. doi: 10.1002/hep.510260723. [DOI] [PubMed] [Google Scholar]
  26. Mathurin P., Moussalli J., Cadranel J. F., Thibault V., Charlotte F., Dumouchel P., Cazier A., Huraux J. M., Devergie B., Vidaud M. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology. 1998 Mar;27(3):868–872. doi: 10.1002/hep.510270333. [DOI] [PubMed] [Google Scholar]
  27. McHutchison J. G., Gordon S. C., Schiff E. R., Shiffman M. L., Lee W. M., Rustgi V. K., Goodman Z. D., Ling M. H., Cort S., Albrecht J. K. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998 Nov 19;339(21):1485–1492. doi: 10.1056/NEJM199811193392101. [DOI] [PubMed] [Google Scholar]
  28. Nevens F., Goubau P., Van Eyken P., Desmyter J., Desmet V., Fevery J. Treatment of decompensated viral hepatitis B-induced cirrhosis with low doses of interferon alpha. Liver. 1993 Feb;13(1):15–19. doi: 10.1111/j.1600-0676.1993.tb00599.x. [DOI] [PubMed] [Google Scholar]
  29. Niederau C., Lange S., Heintges T., Erhardt A., Buschkamp M., Hürter D., Nawrocki M., Kruska L., Hensel F., Petry W. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology. 1998 Dec;28(6):1687–1695. doi: 10.1002/hep.510280632. [DOI] [PubMed] [Google Scholar]
  30. Orito E., Mizokami M., Suzuki K., Ohba K. I., Ohno T., Mizuno M., Iijima Y., Saito H., Nemoto A., Nukuta N. Interferon-alpha therapy for individuals with normal serum alanine aminotransferase levels before treatment. J Gastroenterol Hepatol. 1997 Jan;12(1):58–61. doi: 10.1111/j.1440-1746.1997.tb00347.x. [DOI] [PubMed] [Google Scholar]
  31. Pol S., Couzigou P., Bourlière M., Abergel A., Combis J. M., Larrey D., Tran A., Moussalli J., Poupon R., Berthelot P. A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, France. J Hepatol. 1999 Jul;31(1):1–7. doi: 10.1016/s0168-8278(99)80157-3. [DOI] [PubMed] [Google Scholar]
  32. Poynard T., Bedossa P., Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997 Mar 22;349(9055):825–832. doi: 10.1016/s0140-6736(96)07642-8. [DOI] [PubMed] [Google Scholar]
  33. Poynard T., Leroy V., Cohard M., Thevenot T., Mathurin P., Opolon P., Zarski J. P. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology. 1996 Oct;24(4):778–789. doi: 10.1002/hep.510240405. [DOI] [PubMed] [Google Scholar]
  34. Poynard T., Marcellin P., Lee S. S., Niederau C., Minuk G. S., Ideo G., Bain V., Heathcote J., Zeuzem S., Trepo C. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) Lancet. 1998 Oct 31;352(9138):1426–1432. doi: 10.1016/s0140-6736(98)07124-4. [DOI] [PubMed] [Google Scholar]
  35. Prieto M., Olaso V., Verdú C., Córdoba J., Gisbert C., Rayón M., Carrasco D., Berenguer M., Higón M. D., Berenguer J. Does the healthy hepatitis C virus carrier state really exist? An analysis using polymerase chain reaction. Hepatology. 1995 Aug;22(2):413–417. [PubMed] [Google Scholar]
  36. Reichard O., Norkrans G., Frydén A., Braconier J. H., Sönnerborg A., Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet. 1998 Jan 10;351(9096):83–87. doi: 10.1016/s0140-6736(97)06088-1. [DOI] [PubMed] [Google Scholar]
  37. Salmerón J., Ruiz-Extremera A., Torres C., Rodríguez-Ramos L., Lavín I., Quintero D., Palacios A. Interferon versus ribavirin plus interferon in chronic hepatitis C previously resistant to interferon: a randomized trial. Liver. 1999 Aug;19(4):275–280. doi: 10.1111/j.1478-3231.1999.tb00049.x. [DOI] [PubMed] [Google Scholar]
  38. Schalm S. W., Hansen B. E., Chemello L., Bellobuono A., Brouwer J. T., Weiland O., Cavalletto L., Schvarcz R., Ideo G., Alberti A. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J Hepatol. 1997 May;26(5):961–966. doi: 10.1016/s0168-8278(97)80103-1. [DOI] [PubMed] [Google Scholar]
  39. Seeff L. B. Natural history of hepatitis C. Hepatology. 1997 Sep;26(3 Suppl 1):21S–28S. doi: 10.1002/hep.510260704. [DOI] [PubMed] [Google Scholar]
  40. Serfaty L., Chazouillères O., Pawlotsky J. M., Andreani T., Pellet C., Poupon R. Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity. Gastroenterology. 1996 Jan;110(1):291–295. doi: 10.1053/gast.1996.v110.pm8536870. [DOI] [PubMed] [Google Scholar]
  41. Shahi H. M., Sarin S. K. Prevention of first variceal bleed: an appraisal of current therapies. Am J Gastroenterol. 1998 Dec;93(12):2348–2358. doi: 10.1111/j.1572-0241.1998.00589.x. [DOI] [PubMed] [Google Scholar]
  42. Shakil A. O., Conry-Cantilena C., Alter H. J., Hayashi P., Kleiner D. E., Tedeschi V., Krawczynski K., Conjeevaram H. S., Sallie R., Di Bisceglie A. M. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. Ann Intern Med. 1995 Sep 1;123(5):330–337. doi: 10.7326/0003-4819-123-5-199509010-00002. [DOI] [PubMed] [Google Scholar]
  43. Sherman M. Hepatocellular carcinoma. Gastroenterologist. 1995 Mar;3(1):55–66. [PubMed] [Google Scholar]
  44. Sherman M., Peltekian K. M., Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology. 1995 Aug;22(2):432–438. [PubMed] [Google Scholar]
  45. Shev S., Dhillon A. P., Lindh M., Serléus Z., Wejstål R., Widell A., Norkrans G. The importance of cofactors in the histologic progression of minimal and mild chronic hepatitis C. Liver. 1997 Oct;17(5):215–223. doi: 10.1111/j.1600-0676.1997.tb01021.x. [DOI] [PubMed] [Google Scholar]
  46. Shiffman M. L. Use of high-dose interferon in the treatment of chronic hepatitis C. Semin Liver Dis. 1999;19 (Suppl 1):25–33. [PubMed] [Google Scholar]
  47. Shindo M., Di Bisceglie A. M., Hoofnagle J. H. Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon. Hepatology. 1992 Jun;15(6):1013–1016. doi: 10.1002/hep.1840150607. [DOI] [PubMed] [Google Scholar]
  48. Tam R. C., Pai B., Bard J., Lim C., Averett D. R., Phan U. T., Milovanovic T. Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. J Hepatol. 1999 Mar;30(3):376–382. doi: 10.1016/s0168-8278(99)80093-2. [DOI] [PubMed] [Google Scholar]
  49. Tong M. J., Blatt L. M., McHutchison J. G., Co R. L., Conrad A. Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology. 1997 Dec;26(6):1640–1645. doi: 10.1002/hep.510260637. [DOI] [PubMed] [Google Scholar]
  50. Tong M. J., el-Farra N. S., Reikes A. R., Co R. L. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med. 1995 Jun 1;332(22):1463–1466. doi: 10.1056/NEJM199506013322202. [DOI] [PubMed] [Google Scholar]
  51. Vento S., Garofano T., Renzini C., Cainelli F., Casali F., Ghironzi G., Ferraro T., Concia E. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med. 1998 Jan 29;338(5):286–290. doi: 10.1056/NEJM199801293380503. [DOI] [PubMed] [Google Scholar]
  52. Vial T., Descotes J. Clinical toxicity of the interferons. Drug Saf. 1994 Feb;10(2):115–150. doi: 10.2165/00002018-199410020-00003. [DOI] [PubMed] [Google Scholar]
  53. Yano M., Kumada H., Kage M., Ikeda K., Shimamatsu K., Inoue O., Hashimoto E., Lefkowitch J. H., Ludwig J., Okuda K. The long-term pathological evolution of chronic hepatitis C. Hepatology. 1996 Jun;23(6):1334–1340. doi: 10.1002/hep.510230607. [DOI] [PubMed] [Google Scholar]
  54. Yoshihara H., Noda K., Kamada T. Interrelationship between alcohol intake, hepatitis C, liver cirrhosis, and hepatocellular carcinoma. Recent Dev Alcohol. 1998;14:457–469. doi: 10.1007/0-306-47148-5_23. [DOI] [PubMed] [Google Scholar]
  55. Younossi Z. M., Perrillo R. P. The roles of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with alpha interferons, in the treatment of chronic hepatitis C. Semin Liver Dis. 1999;19 (Suppl 1):95–102. [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES